Loading...
•
Dec 31, 2021
BioCryst Q4 2021 Earnings Report
BioCryst reported Q4 2021 financial results, marked by increased ORLADEYO revenue and investment in Factor D program.
Key Takeaways
BioCryst's Q4 2021 saw a significant increase in total revenue, driven by ORLADEYO sales. The company is focused on growing ORLADEYO revenue and advancing its complement program.
ORLADEYO net revenue reached $46.2 million for the quarter.
Total revenues were $47.2 million, compared to $4.0 million in the fourth quarter of 2020.
Net loss was $17.8 million, or $0.10 per share, compared to a net loss of $60.5 million, or $0.34 per share, for the fourth quarter of 2020.
Cash, cash equivalents, restricted cash and investments totaled $517.8 million as of December 31, 2021.
Forward Guidance
BioCryst anticipates full year 2022 net ORLADEYO revenue to be no less than $250 million. Operating expenses for full year 2022, not including non-cash stock compensation, are expected to be in the range of $440 million to $480 million.
Positive Outlook
- Full year 2022 net ORLADEYO revenue to be no less than $250 million.
Challenges Ahead
- Operating expenses for full year 2022, not including non-cash stock compensation, are expected to be in the range of $440 million to $480 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...